Pylera Capsule
NDC Package 61269-381-12
Package Information
Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) capsules is this combination medication is used with an acid blocker (for example, a proton pump inhibitor such as omeprazole). This formulation utilizes a capsule delivery system. Marketed by H2-pharma, Llc, this product is identified by NDC 61269-381 and is authorized under FDA application NDA050786.
Identification & Billing
- RxCUI: 1294619 - bismuth subcitrate 140 MG / metroNIDAZOLE 125 MG / tetracycline HCl 125 MG Oral Capsule
- RxCUI: 1294619 - bismuth subcitrate 140 MG / metronidazole 125 MG / tetracycline hydrochloride 125 MG Oral Capsule
- RxCUI: 1294621 - PYLERA 140 MG / 125 MG / 125 MG Oral Capsule
- RxCUI: 1294621 - bismuth subcitrate 140 MG / metronidazole 125 MG / tetracycline hydrochloride 125 MG Oral Capsule [Pylera]
- RxCUI: 1294621 - Pylera (bismuth subcitrate 140 MG / metronidazole 125 MG / tetracycline hydrochloride 125 MG) Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 61269 - H2-pharma, Llc
- 61269-381 - Pylera
- 61269-381-12 - 10 BLISTER PACK in 1 BOX / 12 CAPSULE in 1 BLISTER PACK
- 61269-381 - Pylera
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61269-381-12 identifies a specific commercial package of 10 blister pack in 1 box / 12 capsule in 1 blister pack of Pylera, a human prescription drug labeled by H2-pharma, Llc. This capsule is formulated for oral use and contains bismuth subcitrate potassium; metronidazole; tetracycline hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by H2-pharma, Llc on August 18, 2025. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This combination medication is used with an acid blocker (for example, a proton pump inhibitor such as omeprazole). It is used to treat stomach/intestinal ulcers caused by the bacteria H. pylori and to prevent the ulcers from returning. Each capsule contains 3 medications: bismuth subcitrate, metronidazole, and tetracycline. Bismuth subcitrate is often used to treat upset stomach, but it is used in this combination to help stop the growth of bacteria. Metronidazole and tetracycline are antibiotics used to treat a wide variety of bacterial infections. They work by stopping the growth of bacteria. This product treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This product is not recommended for use in children.
How is this H2-pharma, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61269038112. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.